Re: The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials

Authors

  • D. Valenti


Correspondence:

Dino Valenti

Via Nepi 15,

00191 Roma, Italy.

E-mail: dino.valenti99@gmail.com

No abstract is available for this article.

Ancillary